Roberto Salgado

38.9k citations
150 papers · 9.0k · 8 hit papers · h-index 35

Impact in

  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • Cancer Cells and Metastasis
    • HER2/EGFR in Cancer Research
    • CAR-T cell therapy research
    • Cancer Genomics and Diagnostics
    • Breast Cancer Treatment Studies

Papers in

    • Cancer Immunotherapy and Biomarkers 63
    • HER2/EGFR in Cancer Research 27
    • Cancer Cells and Metastasis 19
    • Cancer Genomics and Diagnostics 30
    • Breast Cancer Treatment Studies 29

Roberto Salgado

143 papers receiving 8.9k citations

Roberto Salgado's Hit Papers

Towards targeting the breast cancer immune microenvironment 2024 · 169 citations
1690+4+8Years since publication4008001.2k

Peers

Roberto Salgado
Comparison fields: 5 of 116
  • Oncology 5.3k
  • Cancer Research 2.0k
  • Immunology 2.4k
  • Pulmonary and Respiratory Medicine 1.3k
  • Pathology and Forensic Medicine 475
Replace Priti Lal with:
Priti Lal United States
Marisa Dolled‐Filhart United States
Marc R. Theoret United States
Alessandro Lugli Switzerland
Raanan Berger Israel
Luciana Molinero United States
Joel W. Neal United States
Shumei Kato United States
Roberto Hegg Brazil
Gyungyub Gong South Korea
Roberto Salgado relative to Priti Lal United States Priti Lal's profile →
Citations per field
00.5×3.6×
Priti Lal · 1×
Citations per year

Countries citing papers authored by Roberto Salgado

Since Specialization
Citations

This map shows the geographic impact of Roberto Salgado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Salgado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Salgado more than expected).

Fields of papers citing papers by Roberto Salgado

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Salgado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Salgado. The network helps show where Roberto Salgado may publish in the future.

Co-authors

The 25 scholars most cited alongside Roberto Salgado, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roberto Salgado Line = papers co-authored together Roberto Salgado links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 150 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Hit paper breakdown →
20131231
2
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Hit paper breakdown →
2014967
3
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Hit paper breakdown →
2017676
4
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Hit paper breakdown →
2015652
5
The 2019 World Health Organization classification of tumours of the breast
Hit paper breakdown →
2020573
6
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
Hit paper breakdown →
2015439
7
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Hit paper breakdown →
2020294
8 2018269
9 2001218
10 2016214
11 2016196
12 2015173
13
Towards targeting the breast cancer immune microenvironment
Hit paper breakdown →
2024169
14 2021163
15 2019161
16 2021140
17 2017138
18 2018120
19 2021118
20 2017107

About Roberto Salgado

Roberto Salgado is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 150 papers that have together received 9.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (63 papers), Cancer Genomics and Diagnostics (30 papers), Breast Cancer Treatment Studies (29 papers), HER2/EGFR in Cancer Research (27 papers), Cancer Cells and Metastasis (19 papers), Immunotherapy and Immune Responses (19 papers), Advanced Breast Cancer Therapies (15 papers) and Radiomics and Machine Learning in Medical Imaging (11 papers). The work is most often cited by research in Oncology (5.3k citations), Cancer Research (2.0k citations), Immunology (2.4k citations), Pulmonary and Respiratory Medicine (1.3k citations) and Pathology and Forensic Medicine (475 citations). Roberto Salgado has collaborated with scholars based in Belgium, Australia and United States. Frequent co-authors include Sherene Loi, Christos Sotiriou, Peter Savas, Stefan Michiels, Carsten Denkert, Martine Piccart, Mark J. Smyth, Nicolas Sirtaine, Evandro de Azambuja and Stephen J. Luen. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancer Research, npj Breast Cancer and The Breast.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact